Audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and year ended March 31, 2026
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported strong full-year FY26 results with standalone revenue growing 16.1% to ₹1,06,049.17 Lacs from ₹91,326.13 Lacs in FY25. Net Profit After Tax (PAT) rose 23.9% to ₹10,344.15 Lacs vs ₹8,345.78 Lacs. On a consolidated basis, revenue was ₹1,08,124.24 Lacs and PAT was ₹10,371.52 Lacs (up 26.2% YoY). The Board recommended a final dividend of ₹0.45 per share (45% of face value ₹1). EBITDA margin expanded as profit before tax grew 27% YoY to ₹14,175.89 Lacs while revenue grew at a slower pace, indicating improved operational efficiency. An exceptional charge of ₹307.44 Lacs was recorded for the impact of new Indian Labour Codes. The statutory auditors issued an unmodified (clean) opinion on both standalone and consolidated results. The company also converted Compulsorily Convertible Debentures (CCDs) of ₹33,000 Lacs held by International Finance Corporation into equity in November 2025.
The 23.9% PAT growth and margin expansion signal operational efficiency gains. The clean audit opinion and strong cash flow from operations (₹12,881.59 Lacs) are positives for investors. The dividend recommendation provides immediate shareholder回报. Revenue growth at ~16% slightly missed double-digit expectations but profitability metrics are strong.